Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03395587 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficiency of Vaccination with Lysate-loaded Dendritic Cells in Patients with Newly Diagnosed Glioblastoma

Study acronym: GlioVax
StatusActive, Not Recruiting
PhasePhase 2
Started2018-03-06
View on ClinicalTrials.gov ↗

Amendment history

2024-11-27
Recruiting→Active, Not Recruiting Study Identification, Study Status, Oversight, Study Design, Contacts/Locations, IPDSharing v7
Trial statusRecruiting→Active, Not Recruiting
Primary completion date2026-11-06→2027-05
Completion date2027-03-06→2027-05
Study sitesdetails revised at 6 of 6 sites
Study titlerevised
Efficiency of Vaccination Withwith Lysate-loaded Dendritic Cells in Patients Withwith Newly Diagnosed Glioblastoma
2024-05-13
Study Status, Contacts/Locations v6
Primary completion date2024-09-06→2026-11-06
Completion date2025-06-06→2027-03-06
Study sitescontacts updated at 4 of 6 sites
2022-12-22
Study Status, Contacts/Locations v5
Primary completion date2022-09-06→2024-09-06
Completion date2023-06-06→2025-06-06
Study sites5→6
2020-05-26
Study Status, Contacts/Locations v4
Study sitescontacts updated at 1 of 5 sites
2019-05-16
Study Status, Contacts/Locations v3
Study sitesdetails revised at 1 of 5 sites
Show 2 earlier versions
2019-01-08
Study Status, Contacts/Locations v2
Study sites4→5
2018-05-08
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Primary completion date2022-07-06→2022-09-06
Completion date2023-04-06→2023-06-06
Start dateestimated 2018-01-15→confirmed 2018-03-06
Study sitesdetails revised at 4 of 4 sites
2018-01-09
Original filing
The primary objective of the study is to determine whether overall survival of newly diagnosed glioblastoma patients treated with lysate-loaded, mature dendritic cell vaccines as add-on to the standard of care consisting of resection, radiotherapy with concomitant temozolomide chemotherapy and subsequent adjuvant temozolomide chemotherapy is superior to the treatment with the standard of care alone.
Trial Details
NCT Number NCT03395587
Lead Sponsor Heinrich-Heine University, Duesseldorf
Collaborators: German Federal Ministry of Education and Research
Conditions Glioblastoma
Enrollment 136 participants
Start Date 2018-03-06
Primary Completion 2027-05 (estimated)
Study Completion 2027-05 (estimated)
Updated on ClinicalTrials.gov 2024-12-02